Orion Oyj (HLSE:ORNBV) Shares Just Moved, So What Is Going On?

Orion Oyj (HLSE:ORNBV) moved back into focus after fresh Phase III data showed that darolutamide plus standard therapy improved metastasis free survival in high risk prostate cancer patients compared with placebo based treatment.

That trial update has landed in the middle of a powerful run for Orion Oyj, with the share price at €96.35 after a 1-month share price return of 16.15% and a year to date share price return of 52.21%. Total shareholder return over 3 years is 182.48%, suggesting momentum has been strong as investors reassess both growth prospects and risk around darolutamide and the recent earnings guidance upgrade.

Spot more pharma momentum stories on Simply Wall St by scanning the hand-picked 123 healthcare AI stocks that combine breakthrough drug pipelines with data driven health platforms.

Orion Oyj now appears to be a significantly stronger pharmaceutical platform than it was a year ago. After such a sharp move in the share price, are investors still getting a fair deal, or are they mainly paying for excitement around darolutamide?

Most Popular Narrative: 15% Overvalued

Analysts following Orion Oyj see fair value at €83.67, which trails the current €96.35 share price and frames the latest rally as rich rather than cheap.

The analysts have a consensus price target of €83.67 for Orion Oyj based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €115.0, and the most bearish reporting a price target of just €55.0.

See why 7 investors see Orion Oyj as 15% overvalued.

Result: Fair Value of €83.67 (OVERVALUED)

Still, Orion Oyj could surprise this consensus if Nubeqa outperforms current volume assumptions or if oncology pipeline assets such as ODM-212 deliver stronger than expected trial data.

Find out about the key risks to this Orion Oyj narrative.

Another View: Orion Oyj Through A Cash Flow Lens

Analysts looking at Orion Oyj through earnings multiples see the stock above their €83.67 fair value mark. The Simply Wall St DCF model points in the opposite direction and suggests a future cash flow value of €218.01 per share, well above the current €96.35 price. Which framework do you trust more when those signals pull apart?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Orion Oyj for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 195 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Orion Oyj running hot, this is the moment to look past the headlines, test the numbers, and pressure test your own thesis quickly. To see what is driving optimism, review the 3 key rewards.

Looking for more Orion Oyj style investment ideas?

If Orion Oyj has sharpened your appetite for opportunities, do not stop here. Use the Simply Wall St Screener to quickly surface focused shortlists built around clear, tested criteria.

• Target consistent income by reviewing companies we group as potential payout anchors through the 224 dividend fortresses that may suit income focused portfolios.
• Hunt for quality at a price by reviewing the 610 high quality undiscovered gems that combine strong fundamentals with lower market attention.
• Reduce portfolio stress by filtering for the 223 resilient stocks with low risk scores that score well on resilience and financial strength.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com